MedPath

MRI in Evaluating the Effect of Efaproxiral on the Brain in Patients With Recurrent or Progressive Glioma Enrolled on Clinical Trial NABTT-9806

Not Applicable
Withdrawn
Conditions
Brain and Central Nervous System Tumors
Interventions
Device: magnetic resonance imaging (MRI)
Registration Number
NCT00433472
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brief Summary

RATIONALE: Diagnostic procedures, such as MRI, may help doctors learn how efaproxiral works in the brain and help plan the best treatment.

PURPOSE: This clinical trial is using MRI to evaluate the effect of efaproxiral on the brain in patients with recurrent or progressive glioma receiving treatment on clinical trial NABTT-9806.

Detailed Description

OBJECTIVES:

* Determine whether efaproxiral has a measurable effect on the brain as shown by T2 and/or T2\* MRI in patients with recurrent or progressive malignant glioma enrolled on NABTT-9806.

* Determine predicted oxygenation changes based on observed T2 MRI changes in these patients.

* Determine the effects of this drug on T2 and T2\* MRI relaxation times of normal areas of the brain in these patients.

* Determine baseline oxygen extraction ratios in tumors of patients treated with this drug.

* Determine whether administration of this drug reveals any new tumor- or non-tumor-related abnormalities on T2 and T2\* MRI in these patients.

OUTLINE: This is an open-label, multicenter, pilot study.

Patients receive efaproxiral and carmustine on clinical trial NABTT-9806. During any one course of treatment on that study, patients undergo MRI before oxygen administration (baseline), before efaproxiral infusion, and then every 5 minutes until 1 hour after efaproxiral and carmustine treatment. Data is evaluated for extent and intensity of T2/T2\* changes and oxygen concentration changes in both abnormal and normal brain.

PROJECTED ACCRUAL: A total of 15-48 patients will be accrued for this study within 12-24 months.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
MRI -magnetic resonance imaging (MRI)MRI scan to be complete to look at RSR13 on measurement of T2 and T2\* on MRI Procedure/surgery magnetic resonance imaging (MRI)
Primary Outcome Measures
NameTimeMethod
Measurable effect of efaproxiral on the brain as measured by T2 and/or T2* MRI
Predicted oxygenation changes based on observed T2 MRI changes
Effects of efaproxiral on T2 and T2* MRI relaxation times of normal areas of the brain
Baseline oxygen extraction ratios in tumors
New tumor- or non-tumor-related abnormalities on T2 and T2* MRI
Secondary Outcome Measures
NameTimeMethod
Ā© Copyright 2025. All Rights Reserved by MedPath